[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 7 of about 7
1. Takahashi T, Otani I, Okuda M, Inoue M, Ito K, Sakai M, Koie H, Yamaya Y, Watari T, Sato T, Kanayama K, Tokuriki M: Malignant transformation of T-cell large granular lymphocyte leukemia in a dog. J Vet Med Sci; 2007 Jun;69(6):677-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of T-cell large granular lymphocyte leukemia in a dog.
  • An 8-year-old spayed female Golden Retriever was referred to us for evaluation of mild lymphocytosis.
  • The peripheral lymphocytes were comprised of mostly large granular lymphocytes (LGLs), and flow cytometry showed that they were mostly CD3+8+ T lymphocytes.
  • Clonal rearrangement of the T-cell receptor gene was identified in the peripheral blood, and the dog was therefore diagnosed with LGL chronic leukemia.
  • The dog was subclinical without treatment until hospitalization on day 154, at which point the lymphocytes looked like lymphoblasts and the surface markers changed to CD3-8-.
  • This was regarded as malignant transformation from LGL chronic leukemia to the acute type.
  • Sequential chemotherapy was started, but the dog died on day 190.
  • Necropsy revealed tumor cell infiltration into the heart, skin, and brain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611371.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Pawarode A, Wallace PK, Ford LA, Barcos M, Baer MR: Long-term safety and efficacy of cyclosporin A therapy for T-cell large granular lymphocyte leukemia. Leuk Lymphoma; 2010 Feb;51(2):338-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term safety and efficacy of cyclosporin A therapy for T-cell large granular lymphocyte leukemia.
  • [MeSH-major] Cyclosporine / therapeutic use. Leukemia, Large Granular Lymphocytic / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Immunosuppressive Agents / therapeutic use. Middle Aged. Neutropenia / complications. Neutropenia / drug therapy. Retrospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038217.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


3. Mohan SR, Clemente MJ, Afable M, Cazzolli HN, Bejanyan N, Wlodarski MW, Lichtin AE, Maciejewski JP: Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Haematologica; 2009 Oct;94(10):1407-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia.
  • BACKGROUND: T-cell large granular lymphocytic leukemia is a clonal proliferation of cytotoxic T-lymphocytes which often results in severe cytopenia.
  • Current treatment options favor chronic immunosuppression.
  • Alemtuzumab, a humanized monoclonal antibody against glycophosphatidylinositol-anchored CD52, is approved for patients refractory to therapy in other lymphoid malignancies.
  • DESIGN AND METHODS: We retrospectively examined treatment outcomes in 59 patients with CD8+ T-cell large granular lymphocytic leukemia, 41 of whom required therapy.
  • Eight patients with severe refractory cytopenia despite multiple treatment regimens had been treated with subcutaneous alemtuzumab as salvage therapy.
  • Flow cytometry was used to monitor expression of glycophosphatidylinositol-anchored CD52, CD55, and CD59 as well as to characterize T-cell clonal expansions by T-cell receptor variable beta-chain (Vbeta) repertoire.
  • RESULTS: Analysis of the effects of alemtuzumab revealed remissions with restoration of platelets in one of one patient, red blood cell transfusion independence in three of five patients and improvement of neutropenia in one of three, resulting in an overall response rate of 50% (4/8 patients).
  • Clonal large granular lymphocytes exhibited decreased CD52 expression post-therapy in patients refractory to treatment.
  • Samples of large granular lymphocytes collected prior to therapy also unexpectedly had a significant proportion of CD52-negative cells while a healthy control population had no such CD52 deficiency (p=0.026).
  • CONCLUSIONS: While alemtuzumab may be highly effective in large granular lymphocytic leukemia, prospective serial monitoring for the presence of CD52-deficient clonal cytotoxic T-lymphocytes should be a component of clinical trials investigating the efficacy of this drug.
  • CD52 deficiency may explain lack of response to alemtuzumab, and such therapy may confer a survival advantage to glycophosphatidylinositol-negative clonal cytotoxic T-lymphocytes.

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Jul 1;98(1):165-73 [11418476.001]
  • [Cites] Blood. 2001 Jul 15;98(2):483-5 [11435321.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2001;:259-81 [11722988.001]
  • [Cites] Leuk Lymphoma. 2001 Nov-Dec;42(6):1439-43 [11911433.001]
  • [Cites] Cytotherapy. 2001;3(3):197-201 [12171726.001]
  • [Cites] Cytotherapy. 2001;3(4):261-7 [12171714.001]
  • [Cites] Int J Oncol. 2003 Jan;22(1):33-9 [12469182.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):185-95 [12876667.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):196-200 [12876668.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):785-94 [14608907.001]
  • [Cites] Blood. 2004 Jan 15;103(2):428-34 [12969983.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1548-56 [14576063.001]
  • [Cites] Oncologist. 2004;9(3):247-58 [15169980.001]
  • [Cites] Br J Haematol. 2004 Jul;126(1):55-62 [15198732.001]
  • [Cites] J Exp Med. 2004 Aug 16;200(4):519-25 [15314077.001]
  • [Cites] Blood. 1988 Mar;71(3):822-4 [3345349.001]
  • [Cites] Blood. 1990 Feb 1;75(3):704-8 [2297572.001]
  • [Cites] Lancet. 1992 Sep 26;340(8822):748-52 [1356177.001]
  • [Cites] Blood. 1993 Jul 1;82(1):1-14 [8324214.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1620-7 [8068951.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1487-92 [7632956.001]
  • [Cites] Br J Haematol. 1996 May;93(2):406-8 [8639439.001]
  • [Cites] Br J Rheumatol. 1996 Dec;35(12):1252-5 [9010052.001]
  • [Cites] Biochem J. 1997 Mar 15;322 ( Pt 3):919-25 [9148769.001]
  • [Cites] Br J Haematol. 1997 Apr;97(1):123-6 [9136951.001]
  • [Cites] Lancet. 1999 Nov 13;354(9191):1691-5 [10568572.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):670-3 [10583274.001]
  • [Cites] Blood Rev. 1999 Dec;13(4):230-40 [10741898.001]
  • [Cites] Arthritis Rheum. 2000 Apr;43(4):834-43 [10765928.001]
  • [Cites] Blood. 2000 May 15;95(10):3219-22 [10807792.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):969-71 [11298593.001]
  • [Cites] J Clin Pathol. 1998 Sep;51(9):672-5 [9930071.001]
  • [Cites] Leukemia. 1999 Feb;13(2):230-40 [10025897.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):148-53 [10520035.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1636-43 [15902303.001]
  • [Cites] Leuk Lymphoma. 2005 May;46(5):723-7 [16019510.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2769-80 [15914562.001]
  • [Cites] Cytometry B Clin Cytom. 2006 Mar;70(2):71-81 [16493662.001]
  • [Cites] Haematologica. 2006 May;91(5 Suppl):ECR13 [16709521.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 5):S44-52 [16720203.001]
  • [Cites] Transplantation. 2006 Nov 27;82(10):1342-51 [17130784.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7174-9 [17145843.001]
  • [Cites] Hematology. 2006 Aug;11(4):245-56 [17178663.001]
  • [Cites] Leuk Res. 2007 Jul;31(7):939-45 [17045649.001]
  • [Cites] Immunity. 2007 Oct;27(4):670-84 [17950003.001]
  • [Cites] J Neurol. 2008 Feb;255(2):231-8 [18283404.001]
  • [Cites] Medicine (Baltimore). 1987 Sep;66(5):397-405 [3626848.001]
  • [CommentIn] Haematologica. 2009 Oct;94(10):1341-5 [19794080.001]
  • (PMID = 19794084.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA113972; United States / NCRR NIH HHS / RR / U54 RR019397; United States / NCRR NIH HHS / RR / U54 RR 019397
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  • [Other-IDs] NLM/ PMC2754957
  •  go-up   go-down


Advertisement
4. Moosig F, Schoch R, Kneba M: [T-large granular lymphocyte leukaemia. An important differential diagnosis to Felty's syndrome]. Z Rheumatol; 2006 Sep;65(5):447-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [T-large granular lymphocyte leukaemia. An important differential diagnosis to Felty's syndrome].
  • [Transliterated title] Die T-large Granular Lymphocyte Leukämie (T-LGL-Leukämie). Eine wichtige Differenzialdiagnose zum Felty-syndrom.
  • T-Large Granular Lymphocyte (T-LGL) leukaemia is a rare clonal disease characterized by neutropenia and/or anaemia.
  • Because of its strong association with rheumatoid arthritis (RA), T-LGL leukaemia is an important differential diagnosis to Felty's syndrome.
  • This differentiation might be especially difficult since, in severe RA with extraarticular manifestations, there is often an expanded memory effector T-cell population which can hardly be separated from T-LGL leukaemia cells by means of immunophenotyping.
  • The main criterion for T-LGL leukaemia is the detection of a clonal T-cell-receptor rearrangement by PCR.
  • First-line therapy consists of weekly low-dose methotrexate.
  • There are very limited data from therapy studies.
  • The German CLL study group has initiated a protocol using parenteral low-dose methotrexate as first-line therapy and fludarabine as second-line medication.
  • [MeSH-major] Leukemia, Lymphoid / diagnosis. Leukemia, T-Cell / diagnosis
  • [MeSH-minor] Antirheumatic Agents / therapeutic use. Antiviral Agents / therapeutic use. Arthritis, Rheumatoid / diagnosis. Arthritis, Rheumatoid / drug therapy. Diagnosis, Differential. Felty Syndrome / diagnosis. Humans. Immunosuppressive Agents / therapeutic use. Methotrexate / therapeutic use. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • Genetic Alliance. consumer health - Felty's Syndrome.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Immunol. 2005 Aug;141(2):201-10 [15996183.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1199-200 [8562948.001]
  • [Cites] Arthritis Rheum. 1997 Jun;40(6):1106-14 [9182921.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):857-65 [12786796.001]
  • [Cites] Br J Haematol. 2003 Nov;123(4):613-20 [14616964.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4771-7 [9845544.001]
  • [Cites] Cancer Control. 1998 Jan;5(1):25-33 [10761014.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):935-41 [15958859.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):763-71 [12875995.001]
  • [Cites] J Immunol. 1996 Jun 15;156(12):4609-16 [8648103.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Leuk Res. 2001 Aug;25(8):699-708 [11397476.001]
  • [Cites] Br J Rheumatol. 1996 Dec;35(12):1252-5 [9010052.001]
  • [Cites] Blood. 1998 May 1;91(9):3372-8 [9558395.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1449-53 [12149230.001]
  • [Cites] Br J Haematol. 2002 Mar;116(3):598-600 [11849217.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1861-8 [11696446.001]
  • [Cites] Leuk Res. 2005 Apr;29(4):381-7 [15725471.001]
  • [Cites] Am J Med. 1977 Apr;62(4):588-96 [192076.001]
  • [Cites] Blood. 2000 May 15;95(10):3219-22 [10807792.001]
  • [Cites] Blood. 1993 Jul 1;82(1):1-14 [8324214.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):699-701 [12588360.001]
  • [Cites] Br J Haematol. 2003 Jan;120(1):93-6 [12492582.001]
  • [Cites] Ann Intern Med. 1985 Feb;102(2):169-75 [3966754.001]
  • [Cites] Orv Hetil. 1997 Aug 17;138(33):2075-80 [9304100.001]
  • [Cites] Hematol J. 2003;4(1):18-25 [12692516.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):185-95 [12876667.001]
  • [Cites] Arthritis Rheum. 2000 Apr;43(4):834-43 [10765928.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3198-204 [12480700.001]
  • [Cites] Blood. 1987 Apr;69(4):1204-10 [3103716.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):1026-36 [12648073.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1620-7 [8068951.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):449-53 [14617004.001]
  • [Cites] Oncologist. 2004;9(3):247-58 [15169980.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2164-70 [7919331.001]
  • [Cites] Arthritis Rheum. 1997 Apr;40(4):624-6 [9125243.001]
  • [Cites] J Exp Med. 1994 Feb 1;179(2):609-18 [8294871.001]
  • [Cites] Dtsch Med Wochenschr. 1989 Jul 7;114(27):1064-8 [2525466.001]
  • [Cites] Br J Haematol. 2005 Feb;128(4):490-2 [15686456.001]
  • (PMID = 16450150.001).
  • [ISSN] 0340-1855
  • [Journal-full-title] Zeitschrift fur Rheumatologie
  • [ISO-abbreviation] Z Rheumatol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Antiviral Agents; 0 / Immunosuppressive Agents; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 39
  •  go-up   go-down


5. Olteanu H, Harrington AM, Ramirez S, Kroft SH, Hari P: Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia. Br J Haematol; 2010 Aug;150(4):480-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Large Granular Lymphocytic / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Drug Administration Schedule. Female. Humans. Middle Aged. Purpura, Thrombocytopenic, Idiopathic / chemically induced

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20456357.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


6. Fortune AF, Kelly K, Sargent J, O'Brien D, Quinn F, Chadwick N, Flynn C, Conneally E, Browne P, Crotty GM, Thornton P, Vandenberghe E: Large granular lymphocyte leukemia: natural history and response to treatment. Leuk Lymphoma; 2010 May;51(5):839-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large granular lymphocyte leukemia: natural history and response to treatment.
  • Large granular lymphocyte leukemia (T-LGL) is an indolent T lymphoproliferative disorder that was difficult to diagnose with certainty until clonality testing of the T cell receptor gene became routinely available.
  • We studied the natural history and response to treatment in 25 consecutive patients with T-LGL diagnosed between 2004 and 2008 in which the diagnosis was confirmed by molecular analysis, to define an effective treatment algorithm.
  • The median age at diagnosis was 61 years (range 27-78), with a male to female ratio of 1:1.8 and presenting features of fatigue (n = 13), recurrent infections (n = 9), and/or abnormal blood counts (n = 5).
  • Thirteen patients with symptomatic disease were treated as follows: pentostatin (nine patients), cyclosporine (six patients), methotrexate (three patients), and alemtuzumab in two patients in whom pentostatin was ineffective.
  • Pentostatin was the single most effective therapy, with a response rate of 75% and minimal toxicity.
  • Treatment of T-LGL should be reserved for patients with symptomatic disease, but in this series, pentostatin treatment was less toxic and more effective than cyclosporine or methotrexate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclosporine / therapeutic use. Immunosuppressive Agents / therapeutic use. Leukemia, Large Granular Lymphocytic / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / administration & dosage. Drug Therapy, Combination. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Pentostatin / administration & dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20367569.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Immunosuppressive Agents; 395575MZO7 / Pentostatin; 3A189DH42V / alemtuzumab; 83HN0GTJ6D / Cyclosporine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Sretenovic A, Antic D, Jankovic S, Gotic M, Perunicic-Jovanovic M, Jakovic L, Mihaljevic B: T-cell large granular lymphocytic (T-LGL) leukemia: a single institution experience. Med Oncol; 2010 Jun;27(2):286-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell large granular lymphocytic (T-LGL) leukemia: a single institution experience.
  • BACKGROUND: T-cell large granular lymphocytic (T-LGL) leukemia is a rare lymphoproliferative disease which usually affects elderly people.
  • The clinical course of T-LGL leukemia is generally indolent, with lymphocytosis and splenomegaly in 20-50% patients, hepatomegaly in 5-20% of patients, and less commonly, lymphadenopathy.
  • T-LGL leukemia is associated with immunological abnormalities: rheumatoid factor with or without rheumatoid arthritis (RA), Coombs positive hemolytic anemia, idiopathic thrombocytopenic purpura (ITP), pure red cell aplasia (PRCA), positive anti-nuclear antibodies (ANA), anti-neutrophil cytoplasmic antibodies (ANCA), hypogammaglobulinemia, and polyclonal hypergammaglobulinemia.
  • Aim To compare clinical and laboratory features of T-LGL leukemia patients and their responses to different chemotherapy regimens.
  • METHODS: Six patients (3 males and 3 females) with T-LGL leukemia were analyzed.
  • The diagnosis was based on accepted morphologic criteria, immunophenotype, and polymerase chain reaction (PCR) detection of T-cell receptor (TCR) gene rearrangements.
  • RESULTS: All patients exhibited lymphocytosis, mainly with unusual morphologies, splenomegaly, and elevated serum lactate dehydrogenase (LDH).
  • Three patients were treated with a Fludarabine-Cyclophosphamide (FC) combination as initial therapy while three patients received CHOP.
  • Two patients received more than one treatment regimen.
  • One patient died due to T-LGL leukemia in first year after diagnosis, one patient died 4 years after diagnosis, two patients interrupted their treatment, and two patients are still alive.
  • CONCLUSIONS: Further prospective studies are needed for establishing a gold standard therapy for T-LGL leukemia.
  • [MeSH-major] Leukemia, Large Granular Lymphocytic / blood. Leukemia, Large Granular Lymphocytic / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prednisone / therapeutic use. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2003 Jan;22(1):33-9 [12469182.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1116-9 [1355373.001]
  • [Cites] Ann Intern Med. 1998 Jul 1;129(1):49-58 [9653000.001]
  • [Cites] Blood. 1990 Feb 1;75(3):704-8 [2297572.001]
  • [Cites] Leuk Res. 2007 Jul;31(7):939-45 [17045649.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):570-8 [16795070.001]
  • [Cites] J Clin Pathol. 1998 Sep;51(9):672-5 [9930071.001]
  • [Cites] Oncologist. 2006 Mar;11(3):263-73 [16549811.001]
  • [Cites] Leuk Lymphoma. 2005 May;46(5):723-7 [16019510.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):278-81 [14531909.001]
  • [Cites] Br J Haematol. 1997 Apr;97(1):123-6 [9136951.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2225-6 [17525720.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):699-701 [12588360.001]
  • [Cites] Orv Hetil. 1997 Aug 17;138(33):2075-80 [9304100.001]
  • [Cites] Br J Haematol. 1998 May;101(2):318-24 [9609528.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1620-7 [8068951.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):449-53 [14617004.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2001;:259-81 [11722988.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1969-71 [14976065.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2164-70 [7919331.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2427-38 [15621755.001]
  • (PMID = 19306076.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down






Advertisement